Hematologic Malignancy
Mantle Cell Lymphoma
CI-CAN-00005962MCLExplore in graph →
Hematologic180 active trials5 approved drugs7 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005962MCLExplore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00946374 | Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma(HD-MCL2003) | unknown | Phase 2 | 20 | Heidelberg UniversityOTHER | 1 | Jul 27, 2009 | clinicaltrials |
| NCT00285389 | Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years | completed | Phase 2 | 39 | French Innovative Leukemia OrganisationOTHER | 1 | Feb 12, 2009 |
| clinicaltrials |
| NCT00063713 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 152 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00090090 | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 114 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2008 | clinicaltrials |
| NCT00261612 | Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma | unknown | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | Oct 18, 2006 | clinicaltrials |
| NCT00022945 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | completed | Phase 2 | — | Corixa CorporationINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2009source: clinicaltrials